Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Brief Summary: This 2-arm, randomized, phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have tumors that express the EGFRvIII protein) to the current standard of care (temozolomide) in patients with recently diagnosed glioblastoma, a type of brain cancer.

All patients will be administered temozolomide, the standard treatment for glioblastoma. Half the patients will be randomly assigned to receive rindopepimut and half the patients will be randomly assigned to receive a control called keyhole limpet hemocyanin.

Patients will be treated in a blinded fashion (neither the patient or the doctor will know which arm of the study the patient is on). Patients will be treated until disease progression or intolerance to therapy and all patients will be followed for survival.


Options:
A: Arm Label: Bevacizumab + RT + Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Temozolomide, Radiation: Radiation therapy | Arm Label: Placebo + RT + Temozolomide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Temozolomide, Radiation: Radiation therapy, Drug: Placebo | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab + RT + Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Bevacizumab + RT + Temozolomide, Placebo + RT + Temozolomide | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Bevacizumab + RT + Temozolomide, Placebo + RT + Temozolomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + RT + Temozolomide
B: Arm Label: Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ); Type: EXPERIMENTAL; Interventions: Drug: Temozolomide, Drug: Depatuxizumab mafodotin, Radiation: Radiation | Arm Label: Placebo, Radiation and TMZ; Type: PLACEBO_COMPARATOR; Interventions: Drug: Temozolomide, Radiation: Radiation, Drug: Placebo for ABT-414 | Arm Label: Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ; Type: EXPERIMENTAL; Interventions: Drug: Temozolomide, Drug: Depatuxizumab mafodotin, Radiation: Radiation | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ), Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ, Placebo, Radiation and TMZ | Intervention Type: DRUG; Name: Depatuxizumab mafodotin; Assigned to Arm(s): Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ), Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ | Intervention Type: RADIATION; Name: Radiation; Assigned to Arm(s): Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ), Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ, Placebo, Radiation and TMZ | Intervention Type: DRUG; Name: Placebo for ABT-414; Assigned to Arm(s): Placebo, Radiation and TMZ
C: Arm Label: ABT-414/temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Depatuxizumab mafodotin, Drug: Temozolomide | Arm Label: ABT-414_adult; Type: EXPERIMENTAL; Interventions: Drug: Depatuxizumab mafodotin | Arm Label: Control_lomustine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine | Arm Label: Control_ temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Arm Label: ABT-414_ pediatric; Type: EXPERIMENTAL; Interventions: Drug: Depatuxizumab mafodotin | Intervention Type: DRUG; Name: Depatuxizumab mafodotin; Assigned to Arm(s): ABT-414/temozolomide, ABT-414_ pediatric, ABT-414_adult | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): ABT-414/temozolomide, Control_ temozolomide | Intervention Type: DRUG; Name: Lomustine; Assigned to Arm(s): Control_lomustine
D: Arm Label: Rindopepimut/GM-CSF plus Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF, Drug: Temozolomide | Arm Label: KLH plus Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide, Drug: KLH | Intervention Type: DRUG; Name: Rindopepimut (CDX-110) with GM-CSF; Assigned to Arm(s): Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): KLH plus Temozolomide, Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: KLH; Assigned to Arm(s): KLH plus Temozolomide

Answer: D